“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, our focus is on Valeo Pharma (VPH.C), a specialty pharmaceuticals firm bringing leading therapeutic products in the treatment of such conditions as asthma, Parkinson’s Disease and soft tissue Sarcoma to the Canadian market.
Enjoy!
